Rejected for the 2nd time for the VDPHL01 Clinical Trials (believe it or not!) Chat 3/28/2025
The user was rejected from participating in a clinical trial for an extended-release oral Minoxidil due to having rheumatoid arthritis, despite initially being accepted. They had stopped using Dutasteride and Minoxidil to qualify but continued using other treatments like RU58841 and red light therapy.
View this post in the Community →
Similar Community Posts Join
5 / 164 resultscommunity Prepare to be disappointed by PP405
Delayed release oral minoxidil is seen as a promising advancement for hair loss treatment, offering safer, higher doses and more consistent hair follicle stimulation compared to current options. However, it is not expected to replace finasteride or dutasteride, as it does not prevent androgenetic alopecia.
community People are hyped about PP405 but what about Veradermics phase 2!
Veradermics' phase 2 trial of slow-release oral minoxidil shows promising hair regrowth with minimized side effects, gaining significant attention and funding. PP405 is also noted for its potential as a side-effect-free alternative.
community How Veradermics secured a total of $220 million in series B and C financing for oral minoxidil, I will never understand.....
Veradermics' oral minoxidil shows promise for hair regrowth, with some users reporting significant improvements, while Pelage's PP405 results are less convincing and lack transparency. There is skepticism about both treatments' long-term effectiveness and potential side effects.
community Oral minoxidil - how important is dermastamping?
A trans woman is using 10 mg oral minoxidil, dutasteride, and estradiol for hair regrowth and is also doing dermastamping despite the pain. Users discuss the benefits of dermastamping for serum absorption and hair follicle stimulation, with some expressing surprise at the high minoxidil dosage.
community Veradermics VDPHL01: why isn’t anyone talking about it?
Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.
Related Research
6 / 1000+ results
research Comprehensive Review on Hair Loss and Restorative Techniques: Advances in Diagnostic, Artistry, and Surgical Innovation
Advancements in diagnostics, treatments, and technology have improved hair loss detection and restoration, with some types being reversible.
research New Changes in Pregnancy and Lactation Labeling: Review of Dermatologic Drugs
The new FDA labeling rules provide more detailed drug safety information for pregnant and breastfeeding women, but more data is needed on the risks of many dermatologic drugs.
research MATH+ Multi-Modal Hospital Treatment Protocol for COVID-19 Infection: Clinical and Scientific Rationale
The MATH+ protocol aims to improve COVID-19 outcomes using a combination of specific treatments.
research The Effects of Lower vs Higher Cell Number of Platelet-Rich Plasma on Hair Density and Diameter in Androgenetic Alopecia: A Randomized, Double-Blinded, Placebo, Parallel-Group Half-Scalp IRB-Approved Study
Higher cell number PRP improves hair density and diameter more than lower cell number PRP.
research Cannabinoid Compounds as a Pharmacotherapeutic Option for the Treatment of Non-Cancer Skin Diseases
Cannabinoids like CBD and THC may help treat non-cancer skin diseases, but more research is needed.
research An Update on Drug-Induced Pigmentation
Some drugs can cause skin and hair color changes, often reversible when the drug is stopped.